Briefly introducing our company, Daewoong Pharmaceutical, Co. Ltd, specialized in pharmaceutical manufacturing, R&D, CMO, and Distribution activity to supply pharmaceutical, medical device, and laboratory equipment. Daewoong Pharmaceutical has been named as a leading pharma company in Korea. Ever since our establishment in 1945, Daewoong has remarkably grown to become the top-tier pharmaceutical company in Korea.
Through diversification of our portfolio that integrated into the line of global healthcare, we have received U.S. FDA approval for some of our products, including Meropenem Inj. and Botulinum toxin Biosimilar. Currently, we are operating 13 other companies in our book account with 10 branch offices across the Asia Pacific.

View Daewoong Company presentation

Foistar Tab - finished goods

- API: camostat mesilate, MOA: TMPRSS2 inhibitor, manufactured in KGMP (PIC/S) in Korea).
- Note:
  (*) it has been approved by Korean MoH to go ahead with clinical study phase 3 to prove its efficacy in treating COVID.
  (*) The phase 2a CT is completed and 2b is on going --> expected to have a result by May. 2021
  (*) The phase 3 will be completed by 4Q, 2021. 
  (*) We presume that phase 2b result of Camostat can allow us to pass the Emergency Use Authorization (EUA).

Niclosamide IM Depot Injection

- Indication : Treatment for Covid-19 Diease
- Formulation : IM, Single Injectable
- MOA: SKP2 Inhibitor and STAT3 &TMEM16A inhibitor, manufactured in KGMP (PIC/S) in Korea).
- Note:
  (*) it has been approved by Korean MoH to go ahead with clinical study phase 3 to prove its efficacy in treating COVID.
  (*) The phase 2a CT is completed and 2b is on going --> expected to have a result by July. 2021
  (*) The phase 3 will be completed by 1Q, 2022. 
 (*) We presume that phase 2b result of Niclosamide IM can allow us to pass the Emergency Use Authorization (EUA).